Digest Network Come funziona
Network
/
Società
Ge
Non verificato

GenSight Biologics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

25 comunicati stampa

Guarda tutti i comunicati
20/05/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
15/04/2026
Biotecnologia
Farmaceutica
Salute
Sanità
GenSight Biologics Announces the Filing of its 2025 Universal Registration Document
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
07/04/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
03/04/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
27/03/2026
Mercato azionario
Salute
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
20/03/2026
Industria
Biotecnologia
Farmaceutica
Ottica
Salute
Sanità
Medicina - Varie
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
09/03/2026
Biotecnologia
Farmaceutica
Ottica
Salute
Igiene alimentare
Medicina - Varie
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
Medicina - Varie
Eventi
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
02/12/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
Industria
GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
30/10/2025
Industria
Attrezzature medico-sanitarie
Igiene alimentare
Biotecnologia
Farmaceutica
Salute
Ottica
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0